Systemic therapy of childhood atopic dermatitis

Clinics in Dermatology

Volumn 33, Issue 3, 2015, Pages 289-299

  Slater, Nathaniel A ^a   Morrell, Dean S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIPRURITIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; ETANERCEPT; GAMMA INTERFERON; IMMUNOGLOBULIN; MEPOLIZUMAB; METHOTREXATE; MONTELUKAST; MYCOPHENOLATE MOFETIL; OMALIZUMAB; RETINOID; TOCILIZUMAB; VITAMIN D; DERMATOLOGICAL AGENT;

ARTICLE; ATOPIC DERMATITIS; CHILDHOOD DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFECT; DRUG POTENCY; DRUG RESPONSE; DRUG TREATMENT FAILURE; HUMAN; IMMUNOMODULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PATHOGENESIS; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; SYSTEMIC THERAPY; TREATMENT PLANNING; CHILD; DERMATITIS, ATOPIC;

CHILD; CYCLOSPORINE; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; HUMANS;

EID: 84945464669     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2014.12.005     Document Type: Article

References (87)

1. Flohr C., Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy 2013, 69:3-16.
2. Borchard K.L.A., Orchard D. Systemic therapy of paediatric atopic dermatitis: An update. Australas J Dermatol 2008, 49:123-134. [quiz 135-136].
3. Tan A.U., Gonzalez M.E. Management of severe atopic dermatitis in children. J Drugs Dermatol 2012, 11:1158-1165.
4. Massarano A.A., Hollis S., Devlin J., David T.J. Growth in atopic eczema. Arch Dis Child 1993, 68:677-679.
5. Monti F., Agostini F., Gobbi F., Neri E., Schianchi S., Arcangeli F. Quality of life measures in Italian children with atopic dermatitis and their families. Ital J Pediatr 2011, 37:59.
6. Cookson H., Smith C. Systemic treatment of adult atopic dermatitis. Clin Med 2012, 12:172-176.
7. Denby K.S., Beck L.A. Update on systemic therapies for atopic dermatitis. Curr Opin Allergy Clin Immunol 2012, 12:421-426.
8. Jacobi A., Antoni C., Manger B., Schuler G., Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005, 52(3 Pt 1):522-526.
9. Taïeb A., Seneschal J., Mossalayi M.D. Biologics in atopic dermatitis. J Dtsch Dermatol Ges 2012, 10:174-178.
10. Tintle S., Shemer A., Suárez-Fariñas M., et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol 2011, 128:583-593. [e1-4].
11. Krakowski A.C., Eichenfield L.F., Dohil M.A. Management of atopic dermatitis in the pediatric population. Pediatrics 2008, 122:812-824.
12. National Institute for Health and Clinical Excellence Atopic eczema in children 2007, CG57. [Available at: Http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0009229/. Accessed March 10, 2014].
13. Torley D., Futamura M., Williams H.C., Thomas K.S. What's new in atopic eczema? An analysis of systematic reviews published in 2010-11. Clin Exp Dermatol 2013, 38:449-456.
14. Excellence NI for H and C Atopic eczema in children: Management of atopic eczema in children from birth up to the age of 12 years 2007, RCOG Press, London. CG57 ed.
15. Krejci-Manwaring J., Tusa M.G., Carroll C., et al. Stealth monitoring of adherence to topical medication: Adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007, 56:211-216.
16. Flohr C., Irvine A.D. Systemic therapies for severe atopic dermatitis in children and adults. J Allergy Clin Immunol 2013, 132:774.e6.
17. Darsow U., Wollenberg A., Simon D., et al. Difficult to control atopic dermatitis. World Allergy Organ J 2013, 6:6.
18. Shaw M.G., Burkhart C.N., Morrell D.S. Systemic therapies for pediatric atopic dermatitis: A review for the primary care physician. Pediatr Ann 2009, 38:380-387. [Available at: Http://www.ncbi.nlm.nih.gov/pubmed/19685658. Accessed February 22, 2014].
19. Travers J.B., Kozman A., Yao Y., et al. Treatment outcomes of secondarily impetiginized pediatric atopic dermatitis lesions and the role of oral antibiotics. Pediatr Dermatol 2012, 29:289-296.
20. Simon D., Bieber T. Systemic therapy for atopic dermatitis. Allergy 2013, 69:46-55.
21. Heddle R.J., Atherton D.J. PAPERS AND SHORT REPORTS Combined oral and nasal beclomethasone diproprionate in children with atopic eczema: A randomised controlled trial 1984, 289:651-654.
22. La Rosa M., Musarra I., Ranno C., et al. A randomized, double-blind, placebo-controlled, crossover trial of systemic flunisolide in the treatment of children with severe atopic dermatitis. Curr Ther Res 1995, 56:720-726.
23. Galli E., Chini L., Moschese V., et al. Methylprednisolone bolus: A novel therapy for severe atopic dermatitis. Acta Paediatr 1994, 83:315-317.
24. Ricci G., Dondi A., Patrizi A., Masi M. Systemic therapy of atopic dermatitis in children. Drugs 2009, 69:297-306.
25. Schmitt J., Schäkel K., Fölster-Holst R., et al. Prednisolone versus ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. Br J Dermatol 2010, 162:661-668.
26. Forte W.C.N., Sumita J.M., Rodrigues A.G., Liuson D., Tanaka E. Rebound phenomenon to systemic corticosteroid in atopic dermatitis. Allergol Immunopathol (Madr) 2005, 33:307-311.
27. Lee S.-Y., Shim J.-Y., Kim J.-H., et al. Cyclosporine treatment decreases the percentage of cutaneous lymphocyte antigen (CLA)(+)CD4(+) T cells in children with severe atopic dermatitis. Allergy 2004, 59:1129-1130.
28. Brandt C., Pavlovic V., Radbruch A., Worm M., Baumgrass R. Low-dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis. Allergy 2009, 64:1588-1596.
29. Berth-Jones J., Finlay A.Y., Zaki I., et al. Cyclosporine in severe childhood atopic dermatitis: A multicenter study. J Am Acad Dermatol 1996, 34:1016-1021.
30. Harper J.I., Ahmed I., Barclay G., et al. Cyclosporin for severe childhood atopic dermatitis: Short course versus continuous therapy. Br J Dermatol 2000, 142:52-58.
31. Bemanian M.H., Movahedi M., Farhoudi A., et al. High doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis. Iran J Allergy Asthma Immunol 2005, 4:139-143.
32. Schmitt J., Schmitt N., Meurer M. Cyclosporin in the treatment of patients with atopic eczema-a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007, 21:606-619.
33. Beaumont D.R., Arkwright P.D. Factors determining the effectiveness of oral ciclosporin in the treatment of severe childhood atopic dermatitis. J Dermatolog Treat 2012, 23:318-322.
34. Wolverton S. Comprehensive dermatologic drug therapy [electronic resource] 2013, Edinburgh, Saunders/Elsevier.
35. Roekevisch E., Spuls P.I., Kuester D., Limpens J., Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic review. J Allergy Clin Immunol 2014, 133:429-438.
36. Caufield M., Tom W.L. Oral azathioprine for recalcitrant pediatric atopic dermatitis: Clinical response and thiopurine monitoring. J Am Acad Dermatol 2013, 68:29-35.
37. Waxweiler W.T., Agans R., Morrell D.S. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil. Pediatr Dermatol 2011, 28:689-694.
38. Hon K.-L.E., Ching G.K.W., Leung T.-F., Chow C.-M., Lee K.K.C., Ng P.-C. Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. J Dermatolog Treat 2009, 20:141-145.
39. Berth-Jones J., Takwale A., Tan E., et al. Azathioprine in severe adult atopic dermatitis: A double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002, 147:324-330. [Available at: Http://www.ncbi.nlm.nih.gov/pubmed/12174106. Accessed February 9, 2014.].
40. Meggitt S.J., Gray J.C., Reynolds N.J. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: A double-blind, randomised controlled trial. Lancet 2006, 367:839-846.
41. Murphy L.-A., Atherton D.J. Azathioprine as a treatment for severe atopic eczema in children with a partial thiopurine methyl transferase (TPMT) deficiency. Pediatr Dermatol 2003, 20:531-534. [Available at: Http://www.ncbi.nlm.nih.gov/pubmed/14651577.].
42. Van Egmond R., Barclay M.L., Chin P.K.L., Sies C.W., Florkowski C.M. Biological variation of thiopurine methyltransferase enzyme activity: When has a significant change taken place?. Ann Clin Biochem 2013, 50(Pt 5):473-478.
43. Heller M., Shin H.T., Orlow S.J., Schaffer J.V. Mycophenolate mofetil for severe childhood atopic dermatitis: Experience in 14 patients. Br J Dermatol 2007, 157:127-132.
44. Grundmann-Kollmann M., Podda M., Ochsendorf F., Boehncke W.H., Kaufmann R., Zollner T.M. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001, 137:870-873.
45. Murray M.L., Cohen J.B. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol 2007, 32:23-27.
46. Haeck I.M., Knol M.J., Ten Berge O., van Velsen S.G., de Bruin-Weller M.S., Bruijnzeel-Koomen C.A. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: A randomized controlled trial. J Am Acad Dermatol 2011, 64:1074-1084.
47. Wolverton S. Comprehensive Dermatologic Drug Therapy [electronic resource] 2013, [S.l.: [s.n.]].
48. El-Khalawany M.A., Hassan H., Shaaban D., Ghonaim N., Eassa B. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: A multicenter experience from Egypt. Eur J Pediatr 2013, 172:351-356.
49. Schram M.E., Roekevisch E., Leeflang M.M.G., Bos J.D., Schmitt J., Spuls P.I. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 2011, 128:353-359.
50. Lee J.H., Noh G. Polydesensitisation with reducing elevated serum total IgE by IFN-gamma therapy in atopic dermatitis: IFN-gamma and polydesensitisation (PDS). Cytokine 2013, 64:395-403.
51. Hanifin J.M., Schneider L.C., Leung D.Y.M., et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993, 28:189-197.
52. Jang I.-G., Yang J.-K., Lee H.-J., et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol 2000, 42:1033-1040.
53. Noh G. Pilot Study of Ifn-Γ-Induced Specific Hyposensitization for House Dust Mites in Atopic Dermatitis: Ifn-Γ-Induced Immune Deviation As a New Therapeutic Concept for Atopic Dermatitis. Cytokine 2000, 12:472-476.
54. Turner P.J., Kakakios A., Wong L.-C., Wong M., Campbell D.E. Intravenous immunoglobulin to treat severe atopic dermatitis in children: A case series. Pediatr Dermatol 2012, 29:177-181.
55. Ozen A., Baris S., Karakoc Aydiner E., Yucelten D., Nadir Bahceciler N. Experience with intravenous immunoglobulin in severe childhood atopic dermatitis. Allergol Immunopathol (Madr) 2012, 40:131-133.
56. Jee S.-J., Kim J.-H., Baek H.-S., Lee H.-B., Oh J.-W. Long-term Efficacy of Intravenous Immunoglobulin Therapy for Moderate to Severe Childhood Atopic Dermatitis. Allergy Asthma Immunol Res 2011, 3:89-95.
57. Pei A.Y., Chan H.H., Leung T.F. Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: A pilot study. Pediatr Allergy Immunol 2001, 12:154-158.
58. Hon K.L.E., Leung T.F., Ma K.C., Wong Y., Fok T.F. Brief case series: Montelukast, at doses recommended for asthma treatment, reduces disease severity and increases soluble CD14 in children with atopic dermatitis. J Dermatolog Treat 2005, 16:15-18.
59. Ehlayel M.S., Bener A., Sabbah A. Montelukast treatment in children with moderately severe atopic dermatitis. Eur Ann Allergy Clin Immunol 2007, 39:232-236.
60. Veien N.K., Busch-Sørensen M., Stausbøl-Grøn B. Montelukast treatment of moderate to severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2005, 53:147-149.
61. Friedmann P.S., Palmer R., Tan E., et al. A double-blind, placebo-controlled trial of montelukast in adult atopic eczema. Clin Exp Allergy 2007, 37:1536-1540.
62. Heil P.M., Maurer D., Klein B., Hultsch T., Stingl G. Omalizumab therapy in atopic dermatitis: Depletion of IgE does not improve the clinical course-a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 2010, 8:990-998.
63. Lane J.E., Cheyney J.M., Lane T.N., Kent D.E., Cohen D.J. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006, 54:68-72.
64. Vigo P.G., Girgis K.R., Pfuetze B.L., Critchlow M.E., Fisher J., Hussain I. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 2006, 55:168-170.
65. Kim D.H., Park K.Y., Kim B.J., Kim M.N., Mun S.K. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol 2013, 38:496-500.
66. Hotze M., Baurecht H., Rodríguez E., et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy 2013, 69:132-135.
67. Toledo F., Silvestre J.F., Muñoz C. Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis. Report of four cases. J Eur Acad Dermatol Venereol 2012, 26:1325-1327.
68. Krathen R.A., Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005, 53:338-340.
69. Oldhoff J.M., Darsow U., Werfel T., et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005, 60:693-696.
70. Navarini A.A., French L.E., Hofbauer G.F.L. Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J Allergy Clin Immunol 2011, 128:1128-1130.
71. Buka R.L., Resh B., Roberts B., Cunningham B.B., Friedlander S. Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol 2005, 53:358-359.
72. Weinberg J.M., Siegfried E.C. Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab. Arch Dermatol 2006, 142:555-558.
73. Takiguchi R., Tofte S., Simpson B., et al. Efalizumab for severe atopic dermatitis: A pilot study in adults. J Am Acad Dermatol 2007, 56:222-227.
74. Ibler K., Dam T.N., Gniadecki R., Kragballe K., Jemec G.B.E., Agner T. Efalizumab for severe refractory atopic eczema: Retrospective study on 11 cases. J Eur Acad Dermatol Venereol 2010, 24:837-839.
75. Simon D., Hösli S., Kostylina G., Yawalkar N., Simon H.-U. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008, 121:122-128.
76. Sedivá A., Kayserová J., Vernerová E., et al. Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol 2008, 121:1515-1516. [author reply 1516-1517].
77. Sánchez-Ramón S., Eguíluz-Gracia I., Rodríguez-Mazariego M.E., et al. Sequential combined therapy with omalizumab and rituximab: A new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol 2013, 23:190-196.
78. Mutgi K., Koo J. Update on the role of systemic vitamin D in atopic dermatitis. Pediatr Dermatol 2013, 30:303-307.
79. Heimbeck I., Wjst M., Apfelbacher C.J. Low vitamin D serum level is inversely associated with eczema in children and adolescents in Germany. Allergy 2013, 68:906-910.
80. Chiu Y.E., Havens P.L., Siegel D.H., et al. Serum 25-hydroxyvitamin D concentration does not correlate with atopic dermatitis severity. J Am Acad Dermatol 2013, 69:40-46.
81. Hata T.R., Audish D., Kotol P., et al. A randomized controlled double-blind investigation of the effects of vitamin D dietary supplementation in subjects with atopic dermatitis. J Eur Acad Dermatol Venereol 2013, 3:1-9.
82. Samochocki Z., Bogaczewicz J., Jeziorkowska R., et al. Vitamin D effects in atopic dermatitis. J Am Acad Dermatol 2013, 69:238-244.
83. Ruzicka T., Lynde C.W., Jemec G.B.E., et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: Results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 2008, 158:808-817.
84. Grahovac M., Molin S., Prinz J.C., Ruzicka T., Wollenberg A. Treatment of atopic eczema with oral alitretinoin. Br J Dermatol 2010, 162:217-218.
85. Pavlovsky M., Baum S., Shpiro D., Pavlovsky L., Pavlotsky F. Narrow band UVB: Is it effective and safe for paediatric psoriasis and atopic dermatitis?. J Eur Acad Dermatol Venereol 2011, 25:727-729.
86. Clayton T.H., Clark S.M., Turner D., Goulden V. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol 2007, 32:28-33.
87. Belloni B., Andres C., Ollert M., Ring J., Mempel M. Novel immunologic approaches in the treatment of atopic eczema. Curr Opin Allergy Clin Immunol 2008, 8:423-427.